CTOs on the Move

Orbus Therapeutics

www.orbustherapeutics.com

 
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Orbus Therapeutics raised $18M on 08/21/2015

Similar Companies

Palodex

PaloDEx Group Oy operates in the international healthcare market, focusing on X-ray technology applications used in dental imaging. By offering high-quality imaging solutions that help in making the correct treatment decisions and in improving the level

Med Vsision TeleHealth

Med Vsision TeleHealth is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brisar Delvco

Brisar Delvco is a Paterson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blood Assurance

Blood Assurance is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Charlotte's Optical Co Inc

Charlotte's Optical Co Inc is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.